Management of patients with multiple sclerosis (MS) in the era of disease modifying therapies (DMT) relies heavily on magnetic resonance imaging (MRI) and the support of dedicated multidisciplinary teams (MDTs). While decisions...
Read More
For patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD)...
Read MoreDue to the COVID-19 pandemic, the 2021 American Academy of Neurology Annual Meeting, the world’s premier neurology meeting, will be held in a fully virtual format from April 17-22. It will include: Over 90 expert-led CME...
Read MoreCognitive impairment is a common and disabling feature of multiple sclerosis (MS), but a precise characterization of cognitive phenotypes in MS patients is still lacking. This study identified five cognitive phenotypes:...
Read MoreThe study team compared disability accrual in primary and secondary progressive multiple sclerosis (PPMS, SPMS) in the international MSBase cohort, using multivariable survival models, and applying objective diagnostic criteria...
Read MorePatients with MS may have difficulty performing double task (DT) while walking or causing interference. More research is needed in order to define the role of disability degree in the severity of the interference produced in the...
Read MoreManagement of patients with multiple sclerosis (MS) in the era of disease modifying therapies (DMT) relies heavily on magnetic resonance imaging (MRI). As physicians, decisions are influenced by the reporting prowess of...
Read More
Five-month advantage observed with tebentafusp The novel bispecific fusion protein tebentafusp...
Read More
Disease progression slowed with copanlisib/rituximab combo The combination of copanlisib plus...
Read MoreSunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. MET signaling is a key molecular driver in papillary renal cell...
Read MoreEfficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101 In the phase III JAVELIN Renal 101...
Read MoreOutcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Using the IMDC dataset, patients treated with a 1L...
Read MoreTIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. The TIVO-3 study enrolled subjects with mRCC who failed two or three prior systemic regimens, one of...
Read MoreEnfortumab vedotin (EV) will likely become the new standard of care for treating patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC). A recent phase 3 trial showed that treatment with...
Read MoreAlthough the CheckMate-9ER trial, comparing cabozantinib plus nivolumab to sunitinib in frontline metastatic renal cell carcinoma (mRCC), had recently demonstrated superiority in progression-free survival (PFS) and overall...
Read More
Test your knowledge on results on PsA released at ACR Convergence 2020 – take our quiz and...
Read MoreIn the phase 3 multicenter, open-label, randomized CLEAR trial, lenvatinib in combination with pembrolizumab or everolimus demonstrated significant benefits over sunitinib in patients with advanced renal cell carcinoma (RCC)....
Read More1) In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer ADC trastuzumab deruxtecan (Enhertu) continued to demonstrate favorable data, including a median progression-free...
Read More
Test your knowledge on SABCS 2020 – take our quiz and see how you compare with your...
Read MoreWhich of the following is a preliminary outcome of the retrospective, multi-center observational study in a cohort of Italian MS patients investigating the impact of disease-modifying treatments on COVID-19 course of disease?a)...
Read More
